Directions & Dosage
- Oral administration, take once daily on an empty stomach
- Swallow tablet whole, do not crush, chew or split
- Take at the same time every day
- Strictly use only under supervision of an oncologist
- Not for self-medication or arbitrary dose adjustment
Indications
- First-line treatment of locally advanced or metastatic NSCLC with activating EGFR mutation
- Treatment of locally advanced or metastatic squamous NSCLC after prior platinum-based chemotherapy
Product Advantages
- 2nd generation irreversible EGFR HER2 tyrosine kinase inhibitor
- Broad inhibition of EGFR, HER2 and HER4 signaling pathways
- Irreversible binding, lasting anti-tumor effect
- Effective for common EGFR mutation lung cancer
- Oral tablet form, convenient targeted home medication
Full Product Description
Afatinib Dimaleate 40 mg Tablets is an irreversible second-generation EGFR tyrosine kinase inhibitor (TKI). It permanently blocks epidermal growth factor receptor signaling, inhibits tumor cell proliferation, angiogenesis and metastasis.
It is clinically approved for first-line targeted treatment of EGFR-mutant non-small cell lung cancer and for second-line treatment of squamous non-small cell lung cancer. With strong and stable targeted anti-cancer activity, it is a standard prescription targeted drug for lung cancer standardized treatment.
Storage
Store sealed in cool dry place, protected from light, moisture and high temperature. Keep in original packaging.
Warnings
- Prescription-only anticancer medicine, must be used under oncologist monitoring
- Contraindicated in patients with hypersensitivity to Afatinib Dimaleate or any excipients
- Closely monitor skin reaction, diarrhea, liver and renal function during treatment
- Avoid pregnancy and breastfeeding during medication
- Many drug interactions; inform doctor of all concurrent medicines
- Keep out of reach of children
